TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28597842

Group type: EXPERIMENTAL
Intervention: Lacosamide (initiated at 100 mg/day, uptitrated to 200, 300, or 400 mg/day over 12 weeks)
Number of subjects: 100
Study: 28597967

Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg IV loading dose on day 1, followed by 100 mg daily thereafter)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 70
Study: 28598206

Group type: EXPERIMENTAL
Intervention: PPD-coated beads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human serum albumin-coated beads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncoated beads
Number of subjects: 0
Study: 28598227

Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28598298

Group type: EXPERIMENTAL
Intervention: Exclusive enteral nutrition (EEN) for 12 weeks
Number of subjects: 41
Study: 28598554

Group type: EXPERIMENTAL
Intervention: Testicular cancer survivors
Number of subjects: 158

Group type: COMPARATOR
Intervention: Biological brothers
Number of subjects: 158
Study: 28598987

Group type: EXPERIMENTAL
Intervention: South Asian patients <60 years
Number of subjects: 1068318

Group type: COMPARATOR
Intervention: White patients
Number of subjects: 1068318

Group type: COMPARATOR
Intervention: Black patients
Number of subjects: 1068318

Group type: EXPERIMENTAL
Intervention: South Asian patients
Number of subjects: 1068318
Study: 28599608

Group type: EXPERIMENTAL
Intervention: Brain Function Index (BFI) derived from quantitative EEG (QEEG) features
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Brain Function Index (BFI)
Number of subjects: 720
Study: 28599647

Group type: EXPERIMENTAL
Intervention: Side-lying thrust spinal manipulation (SM) for 12 sessions over 6 weeks.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Hand-held global stiffness (GS) at L3 and automated GS measurements.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Flexion and extension flexion-relaxation ratio (FRR) measurements.
Number of subjects: 82
Study: 28599667

Group type: EXPERIMENTAL
Intervention: Multipolar CRT-d
Number of subjects: 195

Group type: COMPARATOR
Intervention: Bipolar CRT-d
Number of subjects: 195
Study: 28600132

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1·8 mg/kg once every 3 weeks for up to 16 cycles
Number of subjects: 131

Group type: COMPARATOR
Intervention: Physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m2)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 131

Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 131
Study: 28600387

Group type: EXPERIMENTAL
Intervention: Genetic testing
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Broad multiphenotype genetic testing
Number of subjects: 375
Study: 28600603

Group type: EXPERIMENTAL
Intervention: Alcohol dependence (n = 446)
Number of subjects: 700

Group type: COMPARATOR
Intervention: No alcohol dependence (n = 254)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Recent risky alcohol use
Number of subjects: 700
Study: 28600694

Group type: EXPERIMENTAL
Intervention: STARR with Contour Transtar
Number of subjects: 113
Study: 28601192

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-Guided Focused Ultrasound Surgery
Number of subjects: 0
Study: 28601434

Group type: EXPERIMENTAL
Intervention: Moroctocog alfa (AF-CC) 50 IU/kg IV
Number of subjects: 13
Study: 28601641

Group type: EXPERIMENTAL
Intervention: Icatibant (0.4 mg/kg; maximum 30 mg)
Number of subjects: 32
Study: 28601826

Group type: EXPERIMENTAL
Intervention: Metformin and chloroquine
Number of subjects: 0
Study: 28601828

Group type: EXPERIMENTAL
Intervention: Synchronous resection of the primary and liver metastases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resection of the metastatic disease as the first step (liver-first approach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 28602520

Group type: EXPERIMENTAL
Intervention: Low Luminance Questionnaire (LLQ)
Number of subjects: 113
Study: 28602587

Group type: EXPERIMENTAL
Intervention: Dermabrasion with thin split thickness grafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidermal cell suspension spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suction blister epidermal minigrafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minigrafting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultured epithelium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncultured keratinocyte suspension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chip skin grafting
Number of subjects: 0
Study: 28602585

Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg once per day for six consecutive 28-day cycles
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Fedratinib
Number of subjects: 97
Study: 28603514

Group type: EXPERIMENTAL
Intervention: Iontophoresis of phenylephrine on the dorsal forearm
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Iontophoresis of acetylcholine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sympathetic skin responses, autonomic and motor symptoms evaluation
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Skin biopsies
Number of subjects: 52
Study: 28605423

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 balloon-expandable transcatheter heart valve
Number of subjects: 1946
Study: 28605428

Group type: EXPERIMENTAL
Intervention: Carpentier-Edwards PERIMOUNT™ Magna Ease™ aortic valve with RESILIA™ tissue (Model 11000A)
Number of subjects: 689
Study: 28606146

Group type: EXPERIMENTAL
Intervention: SLIMMER diabetes prevention intervention (combined lifestyle intervention with dietary and physical activity components)
Number of subjects: 240
Study: 28606488

Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (B-IPQ)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: B-IPQ 'Consequences' subscale
Number of subjects: 585
Study: 28606598

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 150
Study: 28606966

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 470
Study: 28606999

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 9953

Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 9953

Group type: EXPERIMENTAL
Intervention: Early dual antiplatelet treatment
Number of subjects: 9953

Group type: EXPERIMENTAL
Intervention: PCI timing
Number of subjects: 9953

Group type: EXPERIMENTAL
Intervention: Mortality in high-risk and very-high-risk patients who received PCI
Number of subjects: 9953

Group type: EXPERIMENTAL
Intervention: Very-high-risk patients
Number of subjects: 9953

Group type: COMPARATOR
Intervention: Early risk assessment
Number of subjects: 9953
Study: 28607547

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Domperidone 30 mg (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole 20 mg (group 2)
Number of subjects: 60
Study: 28607686

Group type: EXPERIMENTAL
Intervention: CKD toolkit intervention including practice audit and feedback, printed educational materials, electronic decision support, reminders, and implementation support.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CKD toolkit intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 28607691

Group type: EXPERIMENTAL
Intervention: MIS416 administered once weekly for four weeks, then once weekly for up to 12 weeks at a dose of 500 µg/week.
Number of subjects: 0
Study: 28607708

Group type: EXPERIMENTAL
Intervention: Teriflunomide added to stable-dose GA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) alone
Number of subjects: 0
Study: 28607743

Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta-1a every 2 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 28608617

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks
Number of subjects: 153
Study: 28609404

Group type: EXPERIMENTAL
Intervention: Maternal serology positive infants aged 0-3 months
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Maternal serology positive infants aged 4-8 months
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Maternal serology positive infants/children aged 9-18 months
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Use of maternal serology to define HIV exposure
Number of subjects: 203
Study: 28610605

Group type: EXPERIMENTAL
Intervention: 12 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 24 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Treatment completion
Number of subjects: 93

Group type: COMPARATOR
Intervention: 12 weeks of therapy vs 24 weeks
Number of subjects: 93
Study: 28611030

Group type: EXPERIMENTAL
Intervention: CTG expansion size
Number of subjects: 855
Study: 28611037

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day) for 2 weeks
Number of subjects: 16
Study: 28611125

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28611126

Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study: 28611687

Group type: EXPERIMENTAL
Intervention: Renal Denervation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28611778

Group type: EXPERIMENTAL
Intervention: Peg-Interferon Lambda Treatment
Number of subjects: 0
Study: 28612225

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (EP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 67
Study: 28612237

Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 1454

Group type: COMPARATOR
Intervention: No L-thyroxine
Number of subjects: 1454
Study: 28612680

Group type: EXPERIMENTAL
Intervention: Mobile stroke unit
Number of subjects: 693

Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 693
Study: 28613220

Group type: EXPERIMENTAL
Intervention: Intravitreal injections of Lucentis
Number of subjects: 67
Study: 28614132

Group type: EXPERIMENTAL
Intervention: Chronic opioid users
Number of subjects: 37

Group type: COMPARATOR
Intervention: Opioid-naïve patients
Number of subjects: 37
Study: 28614154

Group type: EXPERIMENTAL
Intervention: High-dose intralesional ziv-aflibercept (0.1 mL to 0.3 mL, 2.5 mg to 7.5 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: High-dose intralesional ziv-aflibercept
Number of subjects: 4
Study: 28614791

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA heterologous prime-boost regimen, delivered intramuscularly with an 8-week interval.
Number of subjects: 24
Study: 28614995

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP) via T-326 inhaler
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS) via nebulizer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Colistimethate sodium (COLI) via nebulizer
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS) and Colistimethate sodium (COLI) via nebulizers
Number of subjects: 60
Study: 28615158

Group type: EXPERIMENTAL
Intervention: PULSED orocutaneous intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: SHAM (non-pulsing) orocutaneous intervention
Number of subjects: 180
Study: 28615265

Group type: EXPERIMENTAL
Intervention: Nutritional intake from food and supplements; specific details on dosage and duration not available.
Number of subjects: 0
Study: 28615277

Group type: EXPERIMENTAL
Intervention: MRI session combined with electroencephalography (EEG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Positron emission tomography session
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) combined with EEG (TMS/EEG) session
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 30
Study: 28615279

Group type: EXPERIMENTAL
Intervention: MOAT (Medicines Optimisation Assessment Tool)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Data collection by pharmacists
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression models
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Bootstrapping
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Simplified scoring system
Number of subjects: 1500
Study: 28615304

Group type: EXPERIMENTAL
Intervention: Ibuprofen exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no ibuprofen exposure)
Number of subjects: 0
Study: 28615374

Group type: EXPERIMENTAL
Intervention: Nutritional status, diet, and stimulation
Number of subjects: 0
Study: 28616291

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (<120 mmHg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional blood pressure control (<140 mmHg)
Number of subjects: 360
Study: 28616804

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 158
Study: 28616853

Group type: EXPERIMENTAL
Intervention: Ceramide dominant therapeutic moisturizer applied twice daily for 12 weeks
Number of subjects: 58
Study: 28617144

Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28618192

Group type: EXPERIMENTAL
Intervention: Patient Buddy App
Number of subjects: 40
Study: 28618293

Group type: EXPERIMENTAL
Intervention: Continuous EEG data collection
Number of subjects: 12
Study: 28618864

Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio in men
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity in men
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity after adjustment
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio and hepatic insulin sensitivity
Number of subjects: 29
Study: 28619014

Group type: EXPERIMENTAL
Intervention: High serum VEGF levels
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: High serum bFGF levels
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Serum VEGF levels
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Histological response, progression-free survival, overall survival
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Blood or urinary bFGF levels
Number of subjects: 269
Study: 28619091

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Postoperative KUB
Number of subjects: 97
Study: 28619116

Group type: EXPERIMENTAL
Intervention: Individual low-threshold physical activity intervention with counseling from a personal coach during and 3 months after chemotherapy
Number of subjects: 18
Study: 28619117

Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia (HoFH)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia (HeFH)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: FH status
Number of subjects: 241
Study: 28619556

Group type: EXPERIMENTAL
Intervention: Topical Janus kinase inhibitors
Number of subjects: 0
Study: 28619704

Group type: EXPERIMENTAL
Intervention: 40 STOPP rules implemented as EMR alerts during a 16-week intervention period.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group did not receive the 40 STOPP rules but received other alerts.
Number of subjects: 28
Study: 28619764

Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Lobectomy using thoracotomy
Number of subjects: 600
Study: 28619986

Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: All 8 risk factors combined
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: All risk factors
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: Most risk factors
Number of subjects: 2125

Group type: EXPERIMENTAL
Intervention: 4 risk factors
Number of subjects: 2125
Study: 28620012

Group type: EXPERIMENTAL
Intervention: Patients with NAFL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with T2DM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON) subjects
Number of subjects: 0
Study: 28620382

Group type: EXPERIMENTAL
Intervention: CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Medium-dose Interferon Alpha 2B
Number of subjects: 31
Study: 28620471

Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched spread (3 g/d)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 240
Study: 28620528

Group type: EXPERIMENTAL
Intervention: Minimal/mild stimulation IVF (mIVF)
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Low oocyte yield group
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: Intermediate oocyte yield group
Number of subjects: 1173

Group type: EXPERIMENTAL
Intervention: High oocyte yield group
Number of subjects: 1173
Study: 28622052

Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: reslizumab
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: mepolizumab (in patients not receiving omalizumab)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: reslizumab (in patients not receiving omalizumab)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: omalizumab (in patients not receiving omalizumab)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: mepolizumab (in mepolizumab-eligible patients not receiving omalizumab)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: reslizumab (in mepolizumab-eligible patients not receiving omalizumab)
Number of subjects: 670
Study: 28622099

Group type: EXPERIMENTAL
Intervention: Concurrent use of energy drinks with alcohol
Number of subjects: 481

Group type: COMPARATOR
Intervention: No use of energy drinks
Number of subjects: 481

Group type: COMPARATOR
Intervention: Energy drinks without concurrent alcohol use
Number of subjects: 481
Study: 28622450

Group type: EXPERIMENTAL
Intervention: Cirrhosis-segmented CirrhoMeter
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: LEV-segmented CirrhoMeter
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Oesophageal Capsule Endoscopy (ECE)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: VariScreen
Number of subjects: 287
Study: 28622454

Group type: EXPERIMENTAL
Intervention: Tocilizumab (intravenous)
Number of subjects: 1216

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 1216
Study: 28622959

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg on days 1 to 21 and panobinostat 15 mg TIW for phase II
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lenalidomide 25 mg and panobinostat 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of panobinostat and lenalidomide
Number of subjects: 24
Study: 28623183

Group type: EXPERIMENTAL
Intervention: EpxDepression
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: EpxAutism
Number of subjects: 9
Study: 28623185

Group type: EXPERIMENTAL
Intervention: iENGAGE behavioral health intervention
Number of subjects: 13
Study: 28623186

Group type: EXPERIMENTAL
Intervention: Adapted versions of the Wii Fit balance board and gaming mat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Off-the-shelf versions of the Wii Fit balance board and gaming mat
Number of subjects: 0
Study: 28623539

Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy (TBB) during research bronchoscopy
Number of subjects: 97
Study: 28623902

Group type: EXPERIMENTAL
Intervention: Markers of atherogenic dyslipidemia (elevated triglyceride levels and low levels of high-density lipoprotein cholesterol)
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Subpopulations with type 2 diabetes mellitus or high cardiovascular disease risk
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Optimal treatment as specified in international guidelines
Number of subjects: 7641
Study: 28623988

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/d) for EHIT prophylaxis
Number of subjects: 306
Study: 28623992

Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence lymphatic imaging
Number of subjects: 1
Study: 28623995

Group type: EXPERIMENTAL
Intervention: Current treatment approaches for SVT (including oral and injectable anticoagulants, pain medication, compression therapy, and no treatment)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Quality of life questionnaires (VEINES-QOL/Sym, EQ-5D-5L)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Incidence of venous thromboembolism
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Combined incidence of major and clinically relevant bleeding events
Number of subjects: 1200
Study: 28624396

Group type: EXPERIMENTAL
Intervention: Hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET) with late gadolinium enhancement (LGE) and FDG
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET)
Number of subjects: 25
Study: 28624388

Group type: EXPERIMENTAL
Intervention: European high-income countries (Europe-High)
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: High-income countries in the rest of the world (rWORLD-High)
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: Middle-income countries (Middle)
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: Income per person
Number of subjects: 2813
Study: 28624608

Group type: EXPERIMENTAL
Intervention: IgE levels
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Blood eosinophil counts
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Fraction of exhaled nitric oxide values
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Sputum eosinophil counts
Number of subjects: 652